DSIP Quick Start
DSIP (Delta Sleep-Inducing Peptide) is a nine-amino-acid neuropeptide first isolated from the cerebral venous blood of sleeping rabbits. It is studied for effects on sleep architecture, stress and cortisol regulation, and pain modulation, mostly in animal models and small early human work. It is typically researched with evening administration.
This guide is an educational research reference. It does not diagnose, treat, or prescribe, and is not medical advice. Consult a licensed clinician before considering any compound.
DSIP Dosing Protocols
The injectable (subcutaneous) and nasal-spray formats are documented as two separate protocols. Research-planning ranges are community-derived and from limited early studies; they are not personal dosing recommendations. DSIP is usually researched in the evening, before the target sleep window.
Injection — Subcutaneous
| Band | Per dose | Frequency |
|---|---|---|
| Low | 100 mcg | Evening |
| Standard | 200 mcg | Evening |
| High | 300 mcg | Evening |
Nasal Spray
| Band | Per dose | # of sprays | Frequency |
|---|---|---|---|
| Low | 100 mcg | 1 spray | Evening |
| Standard | 200 mcg | 2 sprays | Evening |
| High | 300 mcg | 3 sprays | Evening |
DSIP is typically researched in short blocks (e.g., a few weeks) with breaks, rather than continuously. There is no established human cycling standard.
DSIP Reconstitution Guide
DSIP ships as a lyophilized powder. The BAC water volume sets the concentration and draw volume for the injectable vial. Nasal sprays ship pre-mixed and ready to use.
Injection
| BAC | Conc. | 100 mcg |
|---|---|---|
| 2 mL | 5,000 mcg/mL | 0.02 mL · 2 u |
| 3 mL | 3,333 mcg/mL | 0.03 mL · 3 u |
Vial holds up to ~3 mL; 3 mL gives slightly larger draws. Units are U-100.
Reconstitution steps
- Inspect the vial. Confirm label and intact powder.
- Wipe the stoppers. Alcohol swab on both vials.
- Draw BAC water. 2–3 mL into the vial for injection (vial max ~3 mL).
- Inject down the wall. Release water slowly down the inside wall, not onto the powder.
- Swirl, do not shake. Roll gently until clear.
- Refrigerate. Store at 2–8 °C; do not freeze.
How to use the nasal spray
- Prime first use. Pump 2–3 sprays into a tissue until a fine, even mist appears.
- Position. Tilt the head slightly forward; insert the tip just inside one nostril, aimed slightly outward toward the ear — not at the septum.
- Spray and breathe. Press once while breathing in gently; do not sniff hard, which sends the solution down the throat instead of onto the mucosa.
- Alternate nostrils. For multi-spray doses, switch nostrils each spray to spread absorption and limit irritation.
- Count per the protocol. Use the sprays-per-dose shown above; if a dose isn't a whole number, round up.
- Between uses. Wipe the tip, recap, and refrigerate.
How DSIP Works
DSIP's mechanism is not fully characterized. It crosses the blood–brain barrier and has been reported in research to influence sleep architecture, modulate the hypothalamic–pituitary–adrenal (HPA) axis and cortisol, and show neuroprotective and possible analgesic effects. It does not behave like a classic sedative; effects in the literature are described as regulatory rather than hypnotic.
Sleep modulation
Reported effects on sleep architecture rather than simple sedation.
Stress / cortisol
Research describes modulation of the HPA axis and stress hormones.
Neuroprotection
Animal data report antioxidant and neuroprotective activity.
Open question
The receptor target and human clinical relevance remain unsettled.
Who Should Avoid DSIP
Pregnancy & lactation
No human reproductive safety data.
On sleep/CNS medications
Interactions with sedatives or HPA-active drugs are not characterized; review with a clinician.
Endocrine conditions
Given reported HPA-axis effects, those with cortisol-related conditions should be cautious.
Anyone seeking a treatment
DSIP is not an approved therapy for insomnia or any condition.
DSIP Side Effects & Safety
Generally well tolerated
Limited early human and animal data report few adverse effects, but controlled safety data is sparse.
Grogginess / headache
Occasionally reported; timing and dose adjustments are the usual community response.
Injection-site reactions
Mild local reactions can occur; rotate sites.
Quality-control risk
Verify identity and purity against a Certificate of Analysis.
Timeline & What to Monitor
| Timeframe | Commonly tracked | Notes |
|---|---|---|
| Night 1+ | Subjective sleep onset / quality | Effects are evaluated subjectively; no validated peptide-specific measure. |
| Week 1–2 | Sleep pattern, morning grogginess | Adjust timing/dose if grogginess occurs. |
| Ongoing | Stress/mood context | Reported HPA effects mean stress context is relevant to interpret. |
Research Evidence Context
Early human work
Small older studies explored DSIP in sleep and pain/stress contexts with mixed results.
Animal models
Most mechanistic data on sleep, stress, and neuroprotection comes from animal research.
Open question
No modern large RCT establishes efficacy or long-term safety in humans.
Interpretation
Treat planning ranges as research conventions, not validated clinical doses.
Storage & Handling
| State | Storage | Notes |
|---|---|---|
| Lyophilized (powder) | −20 °C long-term; fridge short-term | More stable than reconstituted solution. |
| Reconstituted (liquid) | 2–8 °C | Use within ~3–4 weeks; do not freeze. |
| Appearance | Clear, colorless | Discard cloudy or particulate solutions. |
Mistakes & Troubleshooting
- Morning grogginess. Try a lower dose or earlier evening timing.
- Draws too small to read. Use the 3 mL (3,333 mcg/mL) reconstitution — the vial holds up to ~3 mL.
- Missed dose. Skip it; DSIP is evening-timed, so don't dose late at night to "catch up."
- Left out overnight. Treat reconstituted solution as compromised and discard.
DSIP in Context
| Feature | DSIP | Typical sleep aids |
|---|---|---|
| Class | Endogenous neuropeptide | Sedative-hypnotics / antihistamines |
| Reported action | Sleep/stress modulation (regulatory) | Direct sedation |
| Approval | Not approved | Many approved |
Frequently Asked Questions
What is DSIP?
Delta Sleep-Inducing Peptide, a nine-amino-acid neuropeptide studied for sleep, stress/cortisol, and pain modulation.
How is the injection dosed vs the nasal spray?
Separate protocols, both evening. Injection commonly references 100–300 mcg. The spray delivers 100 mcg per spray, so 1–3 sprays covers the same range.
How is DSIP reconstituted?
For injection, 10 mg in 2 mL BAC water gives 5,000 mcg/mL (100 mcg = 2 units); 3 mL (the vial max) makes small draws slightly easier to read. The spray ships pre-mixed and delivers 100 mcg per spray.
Is DSIP a sedative?
No. Research describes it as modulating sleep architecture and stress signaling rather than acting as a direct sedative-hypnotic.
Is this page medical advice?
No. It is an educational research reference and does not diagnose, treat, or prescribe. Consult a licensed clinician before considering any compound.
References
- Schoenenberger GA, Monnier M. Characterization of a delta-EEG-(sleep)-inducing peptide. Proc Natl Acad Sci USA (1977).
- Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev (1984).
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide: a still unresolved riddle. J Neurochem (2006).
- Bjartell A, et al. DSIP distribution and HPA-axis interactions. Regul Pept / Peptides (review).